Quadria’s $1.07bn Fund III puts $268m toward GCC healthcare deals

Quadria Capital plans to allocate 25% of its US$1.07 billion Fund III to the GCC, putting about US$268 million toward healthcare deals after the fund closed on 27 May 2025.

For UAE healthcare CEOs, CFOs and founders, the number to remember is US$268 million: it signals a new buyer for hospitals, diagnostics, renal care, specialty clinics and healthcare services.

Fund size and deal signal

Quadria Capital, founded in 2012, said on 27 May 2025 that Fund III closed at US$1.07 billion, above its original US$800 million target, according to the firm’s fund close announcement.

Quadria Capital said the fund includes more than US$954 million in primary commitments and US$114 million in committed co-investment capital. The firm also said additional co-investment capacity of US$300 million could take total committed capital to about US$1.3 billion during deployment.

The new fund is about 60% larger than Quadria Capital’s US$600 million Fund II, raised in 2020. Quadria Capital said it manages more than US$4 billion across 27 healthcare investments in India, Vietnam, Indonesia, Malaysia and Singapore.

UAE operators face a more active buyer map

Quadria Capital said Fund III will build a portfolio of about 10 healthcare companies, with both majority and significant minority stakes. That mandate matters in 2025 because UAE providers can face either control-buyer interest or structured growth-capital offers.

Quadria Capital has already named three Fund III investments: Aragen Life Sciences, NephroPlus and Maxivision. The firm said Fund III was nearly 40% deployed, including closed and signed investments, at the time of its 27 May 2025 announcement.

• CEOs should expect more buyer interest in outpatient, dialysis, diagnostics and specialty assets with multi-emirate expansion potential.
• CFOs should benchmark 2025 EBITDA, insurer concentration and revenue-cycle discipline before a sale process starts.
• COOs should review DHA, DOH and MOHAP compliance files before investor diligence begins.
• Founders should watch for platform buyers seeking digital health, home care and clinical workflow tools.

Compliance will shape UAE value

For UAE assets, buyer interest will meet a regulator-by-emirate market in 2025. Dubai Health Authority (DHA) regulates Dubai providers, Department of Health Abu Dhabi (DOH) regulates Abu Dhabi and Al Ain, and Ministry of Health and Prevention (MOHAP) covers federal licensing and Northern Emirates facilities.

Any Quadria Capital-backed platform seeking UAE scale in 2025 or 2026 will need licensing, clinical governance and data controls that satisfy at least one of DHA, DOH or MOHAP, and sometimes more than one.

The practical takeaway for operators is vendor due diligence before talks start. In 2025, a credible sale file should include audited accounts, payer ageing by insurer, doctor productivity by site, malpractice history, cyber controls and regulatory inspection records.

Quadria Capital’s 25% GCC allocation gives the region a new healthcare buyer with about US$268 million to deploy. For UAE executives, clean governance may now affect both valuation and speed to close.